Kura Oncology to Participate in Two Upcoming Investor Conferences
08 September 2020 - 9:30PM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer, today announced
that Troy Wilson, Ph.D., J.D., President and Chief Executive
Officer, is scheduled to participate in two upcoming virtual
investor conferences:
- A fireside chat at the H.C. Wainwright 22nd Annual Global
Investment Conference on September 15, 2020 at 11:30 a.m. ET / 8:30
a.m. PT; and
- A fireside chat at the 2020 Cantor Virtual Global Healthcare
Conference on September 16, 2020 at 4:00 p.m. ET / 1:00 p.m.
PT.
Live audio webcasts of the fireside chats will be available in
the Investors section of Kura’s website at www.kuraoncology.com,
with an archived replay available for 30 days following the
events.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The Company’s pipeline consists of two wholly
owned small molecule drug candidates that target cancer signaling
pathways where there is a strong scientific and clinical rationale
to improve outcomes by identifying those patients most likely to
benefit from treatment. Kura’s most advanced drug candidate is
tipifarnib, a potent, selective and orally bioavailable farnesyl
transferase inhibitor currently in a registration-directed trial
(AIM-HN) in patients with recurrent or metastatic HRAS mutant head
and neck squamous cell carcinoma. The Company’s pipeline is also
highlighted by KO-539, a potent and selective inhibitor of the
menin-KMT2A(MLL) protein-protein interaction currently in a Phase
1/2A clinical trial (KOMET-001) in patients with
relapsed/refractory acute myeloid leukemia. For additional
information about Kura, please visit the Company’s website at
www.kuraoncology.com.
Contacts
Company:Pete De SpainVice President, Investor Relations
&Corporate Communications(858)
500-8803pete@kuraoncology.com
Investors:Robert H. UhlManaging DirectorWestwicke ICR(858)
356-5932robert.uhl@westwicke.com
Media:Jason SparkManaging DirectorCanale Communications(619)
849-6005jason@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2024 to May 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From May 2023 to May 2024